Seeking Alpha

Stemline Therapeutics (STML +6.2%) ramps higher after it prices its 4.2M share public offering...

Stemline Therapeutics (STML +6.2%) ramps higher after it prices its 4.2M share public offering at $14.50 per share, just a 3.3% discount to yesterday's close. The pricing puts the tally on gross proceeds at around $60M. The company intends to use the proceeds to fund ongoing clinical trials of its potential leukemia and lymphoma treatments SL-401 and SL-701, as well as for other general corporate purposes.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)